Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemia

In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?

Bone Marrow Transplantation volume 50, pages 1411–1415 (2015)Cite this article

Subjects

Abstract

Allogeneic hematopoietic transplantation is increasingly used in patients aged 55 years or more with AML. The question of whether outcomes can be improved with an allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD, more than 55 years) is still unanswered. We thus analyzed outcomes in 714 patients aged 55 years and older with AML in first CR (CR1) who received PBSCs after a reduced-intensity conditioning hematopoietic cell transplant from a MUD (n=310) or a MSD (n=404) in a recent period (2005–2010). The 3-year cumulative incidences (CIs) of non-relapse mortality were 17% and 23% with MSD and MUD, respectively (P=0.17). The 3-year CIs of relapse were 37% and 30%, respectively (P=0.12), resulting in a 3-year CI of leukemia-free survival of 46% and 47%, respectively (P=0.51). The 3-year overall survival was 49% with both MSD and MUD. In conclusion, HLA-identical sibling donors aged 55 years or more should not be excluded because of age for patients aged 55 years and older with AML in CR1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011; 17: 401–411.

    Article  PubMed  Google Scholar 

  2. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrozek K et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17: 1796–1803.

    Article  PubMed  Google Scholar 

  3. Gupta V, Tallman MS, He W, Logan BR, Gale RP, Khouri HJ et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116: 1839–1848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstosk K, Szer J et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601–607.

    Article  PubMed  Google Scholar 

  5. Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010; 24: 1276–1282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Robin M, Porcher R, Ades L, Boissel N, Raffoux E, Xhaard A et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. Bone Marrow Transplant 2013; 48: 1296–1301.

    Article  CAS  PubMed  Google Scholar 

  7. Ayuk F, Zabelina T, Wortmann F, Alchaby H, Wolschke C, Lellek H et al. Donor choice according to age for allo-SCT for AML in complete remission. Bone Marrow Transplant 2013; 48: 1028–1032.

    Article  CAS  PubMed  Google Scholar 

  8. Servais S, Porcher R, Xhaard A, Appelbaum FR, Artz A, Benjamin J et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica 2014; 99: 519–526.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Alousi AM, Le-Rademacher J, Saliba RM, Giralt S, Lazarus H, Ho V et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 2013; 121: 2567–2573.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rezvani AR, Storer BE, Guthrie KA, Shoch HG, Maloney DG, Sandmaier B et al. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 105–112.

    Article  PubMed  Google Scholar 

  11. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  14. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  15. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  16. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320.

    Article  CAS  PubMed  Google Scholar 

  17. Kroger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 2013; 27: 604–609.

    Article  CAS  PubMed  Google Scholar 

  18. Paulin T, Ringden O, Nilsson B . Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987; 1: 317–328.

    CAS  PubMed  Google Scholar 

  19. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A et al. Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 448–460.

    Article  PubMed  Google Scholar 

  20. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Devillier R, Crocchiolo R, Castagna L, Furst S, El Cheikh J, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639–645.

    Article  CAS  PubMed  Google Scholar 

  22. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    Article  CAS  PubMed  Google Scholar 

  23. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C . Improved nonrelapse mortality and infection rate with lower dose antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematological malignancies. Biol Blood Marrow Transplant 2009; 15: 1422–1430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014; 49: 389–396.

    Article  CAS  PubMed  Google Scholar 

  25. Blaise D, Castagna L . Do different conditioning regimens really make a difference? Hematology Am Soc Hematol Educ Program 2012; 2012: 237–245.

    PubMed  Google Scholar 

  26. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859–2867.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 308–314.

    Article  CAS  PubMed  Google Scholar 

  28. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405–411.

    Article  PubMed  Google Scholar 

  29. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320–329.

    Article  PubMed  Google Scholar 

  30. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriei P et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115: 1899–1905.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. A Nagler and M Mohty: These authors contributed equally to this work.

Authors and Affiliations

  1. Service d’Hématologie Greffe, AP-HP-Hôpital Saint Louis, Paris, France

    R Peffault de Latour & G Socié

  2. Paris Diderot University, EA 3518, Paris, France

    R Peffault de Latour

  3. ALWP-EBMT, AP-HP-Hôpital Saint Antoine, Paris, France

    M Labopin, A Nagler & M Mohty

  4. Service d’Hématologie Clinique et de Thérapie Cellulaire, AP-HP-Hôpital Saint Antoine, Paris, France

    M Labopin & M Mohty

  5. Universite Pierre et Marie Curie, Paris, France

    M Labopin & M Mohty

  6. INSERM, UMRs 938, Paris, France

    M Labopin & M Mohty

  7. Hematology Department, Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands

    J Cornelissen

  8. CHU Bordeaux-Hôpital Haut-levêque, Pessac, France

    S Vigouroux

  9. BMT unit, Centre for Clinical Haematology-Queen Elizabeth Hospital, Birmingham, UK

    C Craddock

  10. Institut Paoli Calmettes-Unité de Transplantation et de Thérapie Cellulaire-Inserm UMR 891, Marseille, France

    D Blaise

  11. Department of Hematology, Hopital de Purpan-CHU, Toulouse, France

    A Huyn

  12. Bone Marrow Transplant Unit L 4043, Rigshospitalet, Copenhagen, Denmark

    L Vindelov

  13. Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    J Maertens

  14. Department of Hematology, Hopital Hotel Dieu-CHU, Nantes, France

    P Chevallier

  15. CHU Lapeyronie-Service d'Hématologie et Oncologie, Montpellier, France

    N Fegueux

  16. Université Paris Diderot, Paris, France

    G Socié

  17. INSERM 1160, Paris, France

    G Socié

  18. Department of Hematology, University Hospital, Grenoble, France

    J Y Cahn

  19. University Medical Centre UMR 525 CNRS, Grenoble, France

    J Y Cahn

  20. Department of Hematology, Utrecht, The Netherlands,

    E Petersen

  21. Department Internal Medicine Hematology/Oncology, University Hospital Maastricht, Maastricht, The Netherlands,

    H Schouten

  22. Department of Onco-Hematologiy, CHU Hautepierre, Strasbourg, France

    B Lioure

  23. Division of Hematology and BMT, Nottingham City Hospital, Nottingham, UK,

    N Russell

  24. Hospital Clínico-Servicio de Hematología, Salamanca, Spain

    L L Corral

  25. Hematology and BMT Unit, EBMT CIC 813, San Raffaele Scientific Institute, Milano, Italy

    F Ciceri

  26. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel,

    A Nagler

Authors
  1. R Peffault de Latour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Cornelissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Vigouroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Huyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Vindelov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N Fegueux
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Y Cahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Schouten
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. B Lioure
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. N Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. L L Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. F Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Acute Leukemia Working Party of EBMT

Corresponding author

Correspondence to R Peffault de Latour.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

Conception and design: RPL, ML, MM. Provision of study materials and patients: RPL, SV, CC, DB, AH, LV, JM, PC, NF, GS, JYC, EP, HS, BL, NR, LL, FC, AN, MM. Collection and assembly of the data: RPL, ML. Data analysis and interpretation: RPL, ML, MM,AN. Manuscript writing: RPL, ML, MM, AN. Final approval of manuscript: RPL, ML, SV, CC, DB, AH, LV, JM, PC, NF, GS, JYC, EP, HS, BL, NR, LL, FC, AN, MM.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peffault de Latour, R., Labopin, M., Cornelissen, J. et al. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?. Bone Marrow Transplant 50, 1411–1415 (2015). https://doi.org/10.1038/bmt.2015.180

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.180

Search

Advanced search

Quick links